EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma

Lyanne A Delgado-Coka, Lucia Roa-Peña, Sruthi Babu, Michael Horowitz, Emanuel F Petricoin, Lynn M Matrisian iD, Edik M Blais, Natalia Marchenko, Felicia D Allard, Ali Akalin, Wei Jiang, Brent K Larson iD und 5 weitere

American Journal of Clinical Pathology · 03.09.2024 · 162 (3) · 314-326

DOI: 10.1093/ajcp/aqae038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Clinical Pathology, online erschienen am 20.04.2024. Verfasst von Lyanne A Delgado-Coka und 16 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Pathology. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Biomarkers, Tumor, Keratin-17. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To determine the role of keratin 17 (K17) as a predictive biomarker for response to chemotherapy by defining thresholds of K17 expression based on immunohistochemical tests that could be used to optimize therapeutic intervention for patients with pancreatic ductal adenocarcinoma (PDAC).

Methods

We profiled K17 expression, a hallmark of the basal molecular subtype of PDAC, by immunohistochemistry in 2 cohorts of formalin-fixed, paraffin-embedded PDACs (n = 305). We determined a K17 threshold of expression to optimize prognostic stratification according to the lowest Akaike information criterion and explored the potential relationship between K17 and chemoresistance by multivariate predictive analyses.

Results

Patients with advanced-stage, low K17 PDACs treated using 5-fluorouracil (5-FU)–based chemotherapeutic regimens had 3-fold longer survival than corresponding cases treated with gemcitabine-based chemotherapy. By contrast, PDACs with high K17 did not respond to either regimen. The predictive value of K17 was independent of tumor mutation status and other clinicopathologic variables.

Conclusions

The detection of K17 in 10% or greater of PDAC cells identified patients with shortest survival. Among patients with low K17 PDACs, 5-FU–based treatment was more likely than gemcitabine-based therapies to extend survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsBiomarkers, TumorKeratin-17HumansMaleFemalePrognosisMiddle AgedAgedFluorouracilDeoxycytidineGemcitabineImmunohistochemistryAdultAged, 80 and over

Stichwörter der Autor:innen

chemotherapiesimmunohistochemistrypancreatic ductal adenocarcinomapredictive biomarkers

Substanzen

Biomarkers, TumorKeratin-17FluorouracilDeoxycytidineGemcitabineKRT17 protein, human

Autor:innen und Institutionen

  • Departments of Pathology.
  • Departments of Preventative Medicine, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, US.
  • Department of Pathology, School of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia.
  • Center for Applied Proteomics and Molecular Medicine, George Mason University, Fairfax, VA, US.
  • Perthera, McLean, VA, US.
  • Scientific and Medical Affairs, Pancreatic Cancer Action Network, Manhattan Beach, CA, US.

ORCID-Profile: Lynn M Matrisian, Brent K Larson

Förderung

  • NCI NIH HHS

Zitieren

APA

Delgado-Coka, L. A., Roa-Peña, L., Babu, S., Horowitz, M., Petricoin, E. F., Matrisian, L. M., Blais, E. M., Marchenko, N., Allard, F. D., Akalin, A., Jiang, W., Larson, B. K., Hendifar, A. E., Picozzi, V. J., Choi, M., Shroyer, K. R., & Escobar-Hoyos, L. F. (2024). Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma. American Journal of Clinical Pathology, 162(3), 314-326. https://doi.org/10.1093/ajcp/aqae038

Vancouver

Delgado-Coka LA, Roa-Peña L, Babu S, Horowitz M, Petricoin EF, Matrisian LM, et al. Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma. American Journal of Clinical Pathology. 2024;162(3):314-326. doi:10.1093/ajcp/aqae038

BibTeX
@article{DelgadoCoka2024,
  author = {Delgado-Coka, Lyanne A and Roa-Peña, Lucia and Babu, Sruthi and Horowitz, Michael and Petricoin, Emanuel F and Matrisian, Lynn M and Blais, Edik M and Marchenko, Natalia and Allard, Felicia D and Akalin, Ali and Jiang, Wei and Larson, Brent K and Hendifar, Andrew E and Picozzi, Vincent J and Choi, Minsig and Shroyer, Kenneth R and Escobar-Hoyos, Luisa F},
  title = {Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma},
  journal = {American Journal of Clinical Pathology},
  year = {2024},
  volume = {162},
  number = {3},
  pages = {314--326},
  doi = {10.1093/ajcp/aqae038}
}
Kostenlos starten →